Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Kingworld Medicines Group Ltd. ( (HK:1110) ) is now available.
Kingworld Medicines Group Limited has scheduled a board meeting in Hong Kong on 31 March 2026 to review and approve the audited annual results for the financial year ended 31 December 2025. The board will also consider the recommendation of a final dividend and address other corporate matters, signaling an upcoming disclosure of the group’s financial performance and potential returns to shareholders.
The timing of the meeting suggests the company is following its regular reporting cycle, which will provide investors and stakeholders with updated insight into its operational health. Any decision on a final dividend could influence investor sentiment and valuation, as the market assesses the group’s profitability, cash position, and confidence in its future prospects.
The most recent analyst rating on (HK:1110) stock is a Hold with a HK$0.59 price target. To see the full list of analyst forecasts on Kingworld Medicines Group Ltd. stock, see the HK:1110 Stock Forecast page.
More about Kingworld Medicines Group Ltd.
Kingworld Medicines Group Limited operates in the pharmaceutical and healthcare industry through its subsidiaries, focusing on the distribution and sale of medicines and related health products in Hong Kong and mainland China. The group is governed by a board comprising executive and independent non-executive directors, reflecting a conventional listed-company governance structure.
Average Trading Volume: 952,842
Technical Sentiment Signal: Sell
Current Market Cap: HK$297.2M
Learn more about 1110 stock on TipRanks’ Stock Analysis page.